Machine Learning to Predict Interim Response in Pediatric Classical Hodgkin Lymphoma Using Affordable Blood Tests
Jennifer A Geel,Artsiom Hramyka,Jan du Plessis,Yasmin Goga,Anel Van Zyl,Marc G Hendricks,Thanushree Naidoo,Rema Mathew,Lizette Louw,Amy Carr,Beverley Neethling,Tanya M Schickerling,Fareed Omar,Liezl Du Plessis,Elelwani Madzhia,Vhutshilo Netshituni,Katherine Eyal,Thandeka V Z Ngcana,Tom Kelsey,Daynia E Ballott,Monika L Metzger,South African Children's Cancer Study Group,David Stones,Ruellyn Cockroft,Alan Davidson,Anabela Andrade,Ane Buchner,Ann Van Eyssen,Barry van Emmenes,Biance Rowe,Clare Stannard,Cristina Stefan,David Reynders,Diane MacKinnon,Elmarie Mathews,Farieda Desai,Gesami Steytler,Gita Naidu,Janet Poole,Jeanette Parkes,Johani Vermeulen,Karin Lecuona,Karla Thomas,Kate Bennett,Kershinee Reddy,Keshnie Moodley,Komala Pillay,Mariana Kruger,Jaques van Heerden,Linda Wainwright,Leila Schoonraad,Lourens de Jager,Mairi Bassingthwaighte,Manickavallie Vaithilingum,Nicolene Moonsamy,Oloko Wedi,Palessa Radebe,Ronelle Uys,Stelios Poyiadjis,Thandeka Ngcana,Rajendra Thejpal,Rosemarie Schwyzer,Johannes Du Plessis,Candice Hendricks,Pieter Hesseling,Barry Vanemmenes,Judy Schoeman,Mohamed Adamjee,Milind Chitnis,Pat Hartley,Wendy Mathiassen,Alistair Millar,Colleen Wright,Nadia Beringer,Ngoakoana Mahlachana,Thandeka Nkabi,Jade Flood,Mampoi Jonas,Hamidah Van Staaden,Thurandrie Naicker,Pawel Schubert,Bulelwa Masoka
DOI: https://doi.org/10.1200/GO.23.00435
Abstract:Purpose: Response assessment of classical Hodgkin lymphoma (cHL) with positron emission tomography-computerized tomography (PET-CT) is standard of care in well-resourced settings but unavailable in most African countries. We aimed to investigate correlations between changes in PET-CT findings at interim analysis with changes in blood test results in pediatric patients with cHL in 17 South African centers. Methods: Changes in ferritin, lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR), albumin, total white cell count (TWC), absolute lymphocyte count (ALC), and absolute eosinophil count were compared with PET-CT Deauville scores (DS) after two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine in 84 pediatric patients with cHL. DS 1-3 denoted rapid early response (RER) while DS 4-5 denoted slow early response (SER). Missing values were imputed using the k-nearest neighbor algorithm. Baseline and follow-up blood test values were combined into a single difference variable. Data were split into training and testing sets for analysis using Python scikit-learn 1.2.2 with logistic regression, random forests, naïve Bayes, and support vector machine classifiers. Results: Random forest analysis achieved the best validated test accuracy of 73% when predicting RER or SER from blood samples. When applied to the full data set, the optimal model had a predictive accuracy of 80% and a receiver operating characteristic AUC of 89%. The most predictive variable was the differences in ALC, contributing 21% to the model. Differences in ferritin, LDH, and TWC contributed 15%-16%. Differences in ESR, hemoglobin, and albumin contributed 11%-12%. Conclusion: Changes in low-cost, widely available blood tests may predict chemosensitivity for pediatric cHL without access to PET-CT, identifying patients who may not require radiotherapy. Changes in these nonspecific blood tests should be assessed in combination with clinical findings and available imaging to avoid undertreatment.